Functional evaluation of therapeutic response for a mouse model of medulloblastoma

Aislynn K. Samano, Sachiko Ohshima-Hosoyama, Thomas G. Whitney, Suresh I. Prajapati, Aoife Kilcoyne, Eri Taniguchi, William W. Morgan, Laura D. Nelon, Ai Ling Lin, Osamu Togao, Inkyung Jung, Brian P. Rubin, Brent M. Nowak, Timothy Q. Duong, Charles Keller

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Medulloblastoma is an aggressive childhood cerebellar tumor. We recently reported a mouse model with conditional deletion of Patched1 gene that recapitulates many characteristics of the human medulloblastoma. Qualitative symptoms observed in the mouse model include irregular stride length, impaired cranial nerve function and decreased motor coordination and performance. In our current study, several quantitative behavioral assays including a mouse rotarod, a forced air challenge, a screen inversion test, a horizontal wire test, and stride length analysis were evaluated to determine the most sensitive and cost-effective functional assay for impaired neuromotor behavior associated with disease progression. Magnetic resonance imaging (MRI) was used to confirm and monitor tumor growth and as an anatomical biomarker for therapeutic response. Wild type mice or medulloblastoma-prone, conditional Patched1 knockout mice were observed by behavioral assays and MRI from postnatal weeks 3-6. Bortezomib treatment was administered during this period and therapeutic response was assessed using cerebellar volumes at the end of treatment. Of the behavioral tests assessed in this study, stride length analysis was best able to detect differences between tumor-prone mice and wild type mice as early as postnatal day 37 (P = 0.003). Significant differences between stride lengths of bortezomib treated and control tumor-bearing mice could be detected as early as postnatal day 42 (P = 0.020). Cerebellar volumes measured by MRI at the end of treatment validated the therapeutic effects seen by behavioral tests (P = 0.03). These findings suggest that stride length analysis may serve as one of the more sensitive and cost-effective method for assessing new therapeutic compounds in this and other preclinical model of brain tumors.

Original languageEnglish (US)
Pages (from-to)829-840
Number of pages12
JournalTransgenic Research
Volume19
Issue number5
DOIs
StatePublished - 2010

Fingerprint

Medulloblastoma
animal models
therapeutics
mice
neoplasms
magnetic resonance imaging
Magnetic Resonance Imaging
assays
Therapeutics
testing
Cerebellar Neoplasms
gene deletion
Costs and Cost Analysis
Neoplasms
wire
Cranial Nerves
disease course
childhood
Gene Deletion
Therapeutic Uses

Keywords

  • Brain tumor
  • Cerebellum
  • Genetically-engineered mouse model
  • Medulloblastoma
  • MRI

ASJC Scopus subject areas

  • Biotechnology
  • Genetics
  • Agronomy and Crop Science
  • Animal Science and Zoology

Cite this

Samano, A. K., Ohshima-Hosoyama, S., Whitney, T. G., Prajapati, S. I., Kilcoyne, A., Taniguchi, E., ... Keller, C. (2010). Functional evaluation of therapeutic response for a mouse model of medulloblastoma. Transgenic Research, 19(5), 829-840. https://doi.org/10.1007/s11248-010-9361-1

Functional evaluation of therapeutic response for a mouse model of medulloblastoma. / Samano, Aislynn K.; Ohshima-Hosoyama, Sachiko; Whitney, Thomas G.; Prajapati, Suresh I.; Kilcoyne, Aoife; Taniguchi, Eri; Morgan, William W.; Nelon, Laura D.; Lin, Ai Ling; Togao, Osamu; Jung, Inkyung; Rubin, Brian P.; Nowak, Brent M.; Duong, Timothy Q.; Keller, Charles.

In: Transgenic Research, Vol. 19, No. 5, 2010, p. 829-840.

Research output: Contribution to journalArticle

Samano, AK, Ohshima-Hosoyama, S, Whitney, TG, Prajapati, SI, Kilcoyne, A, Taniguchi, E, Morgan, WW, Nelon, LD, Lin, AL, Togao, O, Jung, I, Rubin, BP, Nowak, BM, Duong, TQ & Keller, C 2010, 'Functional evaluation of therapeutic response for a mouse model of medulloblastoma', Transgenic Research, vol. 19, no. 5, pp. 829-840. https://doi.org/10.1007/s11248-010-9361-1
Samano AK, Ohshima-Hosoyama S, Whitney TG, Prajapati SI, Kilcoyne A, Taniguchi E et al. Functional evaluation of therapeutic response for a mouse model of medulloblastoma. Transgenic Research. 2010;19(5):829-840. https://doi.org/10.1007/s11248-010-9361-1
Samano, Aislynn K. ; Ohshima-Hosoyama, Sachiko ; Whitney, Thomas G. ; Prajapati, Suresh I. ; Kilcoyne, Aoife ; Taniguchi, Eri ; Morgan, William W. ; Nelon, Laura D. ; Lin, Ai Ling ; Togao, Osamu ; Jung, Inkyung ; Rubin, Brian P. ; Nowak, Brent M. ; Duong, Timothy Q. ; Keller, Charles. / Functional evaluation of therapeutic response for a mouse model of medulloblastoma. In: Transgenic Research. 2010 ; Vol. 19, No. 5. pp. 829-840.
@article{c88ac2e53f9b4b2db577cf61614fc389,
title = "Functional evaluation of therapeutic response for a mouse model of medulloblastoma",
abstract = "Medulloblastoma is an aggressive childhood cerebellar tumor. We recently reported a mouse model with conditional deletion of Patched1 gene that recapitulates many characteristics of the human medulloblastoma. Qualitative symptoms observed in the mouse model include irregular stride length, impaired cranial nerve function and decreased motor coordination and performance. In our current study, several quantitative behavioral assays including a mouse rotarod, a forced air challenge, a screen inversion test, a horizontal wire test, and stride length analysis were evaluated to determine the most sensitive and cost-effective functional assay for impaired neuromotor behavior associated with disease progression. Magnetic resonance imaging (MRI) was used to confirm and monitor tumor growth and as an anatomical biomarker for therapeutic response. Wild type mice or medulloblastoma-prone, conditional Patched1 knockout mice were observed by behavioral assays and MRI from postnatal weeks 3-6. Bortezomib treatment was administered during this period and therapeutic response was assessed using cerebellar volumes at the end of treatment. Of the behavioral tests assessed in this study, stride length analysis was best able to detect differences between tumor-prone mice and wild type mice as early as postnatal day 37 (P = 0.003). Significant differences between stride lengths of bortezomib treated and control tumor-bearing mice could be detected as early as postnatal day 42 (P = 0.020). Cerebellar volumes measured by MRI at the end of treatment validated the therapeutic effects seen by behavioral tests (P = 0.03). These findings suggest that stride length analysis may serve as one of the more sensitive and cost-effective method for assessing new therapeutic compounds in this and other preclinical model of brain tumors.",
keywords = "Brain tumor, Cerebellum, Genetically-engineered mouse model, Medulloblastoma, MRI",
author = "Samano, {Aislynn K.} and Sachiko Ohshima-Hosoyama and Whitney, {Thomas G.} and Prajapati, {Suresh I.} and Aoife Kilcoyne and Eri Taniguchi and Morgan, {William W.} and Nelon, {Laura D.} and Lin, {Ai Ling} and Osamu Togao and Inkyung Jung and Rubin, {Brian P.} and Nowak, {Brent M.} and Duong, {Timothy Q.} and Charles Keller",
year = "2010",
doi = "10.1007/s11248-010-9361-1",
language = "English (US)",
volume = "19",
pages = "829--840",
journal = "Transgenic Research",
issn = "0962-8819",
publisher = "Springer Netherlands",
number = "5",

}

TY - JOUR

T1 - Functional evaluation of therapeutic response for a mouse model of medulloblastoma

AU - Samano, Aislynn K.

AU - Ohshima-Hosoyama, Sachiko

AU - Whitney, Thomas G.

AU - Prajapati, Suresh I.

AU - Kilcoyne, Aoife

AU - Taniguchi, Eri

AU - Morgan, William W.

AU - Nelon, Laura D.

AU - Lin, Ai Ling

AU - Togao, Osamu

AU - Jung, Inkyung

AU - Rubin, Brian P.

AU - Nowak, Brent M.

AU - Duong, Timothy Q.

AU - Keller, Charles

PY - 2010

Y1 - 2010

N2 - Medulloblastoma is an aggressive childhood cerebellar tumor. We recently reported a mouse model with conditional deletion of Patched1 gene that recapitulates many characteristics of the human medulloblastoma. Qualitative symptoms observed in the mouse model include irregular stride length, impaired cranial nerve function and decreased motor coordination and performance. In our current study, several quantitative behavioral assays including a mouse rotarod, a forced air challenge, a screen inversion test, a horizontal wire test, and stride length analysis were evaluated to determine the most sensitive and cost-effective functional assay for impaired neuromotor behavior associated with disease progression. Magnetic resonance imaging (MRI) was used to confirm and monitor tumor growth and as an anatomical biomarker for therapeutic response. Wild type mice or medulloblastoma-prone, conditional Patched1 knockout mice were observed by behavioral assays and MRI from postnatal weeks 3-6. Bortezomib treatment was administered during this period and therapeutic response was assessed using cerebellar volumes at the end of treatment. Of the behavioral tests assessed in this study, stride length analysis was best able to detect differences between tumor-prone mice and wild type mice as early as postnatal day 37 (P = 0.003). Significant differences between stride lengths of bortezomib treated and control tumor-bearing mice could be detected as early as postnatal day 42 (P = 0.020). Cerebellar volumes measured by MRI at the end of treatment validated the therapeutic effects seen by behavioral tests (P = 0.03). These findings suggest that stride length analysis may serve as one of the more sensitive and cost-effective method for assessing new therapeutic compounds in this and other preclinical model of brain tumors.

AB - Medulloblastoma is an aggressive childhood cerebellar tumor. We recently reported a mouse model with conditional deletion of Patched1 gene that recapitulates many characteristics of the human medulloblastoma. Qualitative symptoms observed in the mouse model include irregular stride length, impaired cranial nerve function and decreased motor coordination and performance. In our current study, several quantitative behavioral assays including a mouse rotarod, a forced air challenge, a screen inversion test, a horizontal wire test, and stride length analysis were evaluated to determine the most sensitive and cost-effective functional assay for impaired neuromotor behavior associated with disease progression. Magnetic resonance imaging (MRI) was used to confirm and monitor tumor growth and as an anatomical biomarker for therapeutic response. Wild type mice or medulloblastoma-prone, conditional Patched1 knockout mice were observed by behavioral assays and MRI from postnatal weeks 3-6. Bortezomib treatment was administered during this period and therapeutic response was assessed using cerebellar volumes at the end of treatment. Of the behavioral tests assessed in this study, stride length analysis was best able to detect differences between tumor-prone mice and wild type mice as early as postnatal day 37 (P = 0.003). Significant differences between stride lengths of bortezomib treated and control tumor-bearing mice could be detected as early as postnatal day 42 (P = 0.020). Cerebellar volumes measured by MRI at the end of treatment validated the therapeutic effects seen by behavioral tests (P = 0.03). These findings suggest that stride length analysis may serve as one of the more sensitive and cost-effective method for assessing new therapeutic compounds in this and other preclinical model of brain tumors.

KW - Brain tumor

KW - Cerebellum

KW - Genetically-engineered mouse model

KW - Medulloblastoma

KW - MRI

UR - http://www.scopus.com/inward/record.url?scp=77956479811&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956479811&partnerID=8YFLogxK

U2 - 10.1007/s11248-010-9361-1

DO - 10.1007/s11248-010-9361-1

M3 - Article

C2 - 20107895

AN - SCOPUS:77956479811

VL - 19

SP - 829

EP - 840

JO - Transgenic Research

JF - Transgenic Research

SN - 0962-8819

IS - 5

ER -